84 related articles for article (PubMed ID: 3504722)
1. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group.
Boonekamp PM; Löwik CW; van der Wee-Pals LJ; van Wijk-van Lennep ML; Bijvoet OL
Bone Miner; 1987 Feb; 2(1):29-42. PubMed ID: 3504722
[TBL] [Abstract][Full Text] [Related]
2. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix.
Boonekamp PM; van der Wee-Pals LJ; van Wijk-van Lennep MM; Thesing CW; Bijvoet OL
Bone Miner; 1986 Feb; 1(1):27-39. PubMed ID: 3508715
[TBL] [Abstract][Full Text] [Related]
3. Modulation of PTH-stimulated osteoclastic resorption by bisphosphonates in fetal mouse bone explants.
van der Pluijm G; Löwik CW; de Groot H; Alblas MJ; van der Wee-Pals LJ; Bijvoet OL; Papapoulos SE
J Bone Miner Res; 1991 Nov; 6(11):1203-10. PubMed ID: 1839590
[TBL] [Abstract][Full Text] [Related]
4. Effects of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate on mouse osteoclasts.
Marshall MJ; Wilson AS; Davie MW
J Bone Miner Res; 1990 Sep; 5(9):955-62. PubMed ID: 2281826
[TBL] [Abstract][Full Text] [Related]
5. Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo.
van der Pluijm G; Binderup L; Bramm E; van der Wee-Pals L; De Groot H; Binderup E; Löwik C; Papapoulos S
J Bone Miner Res; 1992 Aug; 7(8):981-6. PubMed ID: 1442212
[TBL] [Abstract][Full Text] [Related]
6. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate.
Löwik CW; van der Pluijm G; van der Wee-Pals LJ; van Treslong-De Groot HB; Bijvoet OL
J Bone Miner Res; 1988 Apr; 3(2):185-92. PubMed ID: 3213614
[TBL] [Abstract][Full Text] [Related]
7. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy.
Sato M; Grasser W
J Bone Miner Res; 1990 Jan; 5(1):31-40. PubMed ID: 2106763
[TBL] [Abstract][Full Text] [Related]
8. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro.
Carano A; Teitelbaum SL; Konsek JD; Schlesinger PH; Blair HC
J Clin Invest; 1990 Feb; 85(2):456-61. PubMed ID: 2105340
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of action of the bisphosphonates.
Fleisch H
Medicina (B Aires); 1997; 57 Suppl 1():65-75. PubMed ID: 9567358
[TBL] [Abstract][Full Text] [Related]
11. Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.
Yu X; Schøller J; Foged NT
Bone; 1996 Oct; 19(4):339-45. PubMed ID: 8894139
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae.
Rogers MJ; Xiong X; Brown RJ; Watts DJ; Russell RG; Bayless AV; Ebetino FH
Mol Pharmacol; 1995 Feb; 47(2):398-402. PubMed ID: 7870050
[TBL] [Abstract][Full Text] [Related]
13. Differential action of the bisphosphonates (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) and disodium dichloromethylidene bisphosphonate (Cl2MDP) on rat macrophage-mediated bone resorption in vitro.
Reitsma PH; Teitelbaum SL; Bijvoet OL; Kahn AJ
J Clin Invest; 1982 Nov; 70(5):927-33. PubMed ID: 7130396
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates suppress bone resorption by a direct effect on early osteoclast precursors without affecting the osteoclastogenic capacity of osteogenic cells: the role of protein geranylgeranylation in the action of nitrogen-containing bisphosphonates on osteoclast precursors.
Van Beek ER; Löwik CW; Papapoulos SE
Bone; 2002 Jan; 30(1):64-70. PubMed ID: 11792566
[TBL] [Abstract][Full Text] [Related]
15. Molecular mechanisms of action of bisphosphonates: current status.
Roelofs AJ; Thompson K; Gordon S; Rogers MJ
Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
Uchiyama S; Yamaguchi M
Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
[TBL] [Abstract][Full Text] [Related]
17. The cellular mechanism of action of bisphosphonates.
Hughes DE; Mian M; Guilland-Cumming DF; Russell RG
Drugs Exp Clin Res; 1991; 17(2):109-14. PubMed ID: 1864224
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of osteoclast mediated bone resorption--rationale for the design of new therapeutics.
Väänänen K
Adv Drug Deliv Rev; 2005 May; 57(7):959-71. PubMed ID: 15876398
[TBL] [Abstract][Full Text] [Related]
19. In vitro comparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts.
Kellinsalmi M; Mönkkönen H; Mönkkönen J; Leskelä HV; Parikka V; Hämäläinen M; Lehenkari P
Basic Clin Pharmacol Toxicol; 2005 Dec; 97(6):382-91. PubMed ID: 16364054
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
